| scholarly article | Q13442814 |
| P356 | DOI | 10.1001/JAMA.2009.1755 |
| P8608 | Fatcat ID | release_lcnkt4aulzc33nqhpngoszyeou |
| P932 | PMC publication ID | 4139149 |
| P698 | PubMed publication ID | 19952320 |
| P50 | author | Jean-Nicolas Vauthey | Q43369878 |
| P2093 | author name string | Harmeet Kaur | |
| Steven A Curley | |||
| Chusilp Charnsangavej | |||
| Dipen M Maru | |||
| Scott Kopetz | |||
| Eddie K Abdalla | |||
| Yun Shin Chun | |||
| Piyaporn Boonsirikamchai | |||
| Evelyne M Loyer | |||
| Martin Palavecino | |||
| P2860 | cites work | Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 |
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. | Q34579127 | ||
| Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. | Q34590731 | ||
| Imaging of angiogenesis: clinical techniques and novel imaging methods | Q36688132 | ||
| Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. | Q37303627 | ||
| Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan | Q37594926 | ||
| Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome | Q44019896 | ||
| Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? | Q45166892 | ||
| Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy | Q46107233 | ||
| Functional CT for quantifying tumor perfusion in antiangiogenic therapy in a rat model | Q46720626 | ||
| Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. | Q46817228 | ||
| Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases | Q46931957 | ||
| Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. | Q53522081 | ||
| Peripheral low-density area of hepatic tumors: CT-pathologic correlation | Q70141201 | ||
| Hepatic colorectal metastases: correlation of MR imaging and pathologic appearance | Q70225726 | ||
| In vivo assessment of neovascularization of liver metastases using perfusion CT | Q74620633 | ||
| Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery | Q79294401 | ||
| Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? | Q80980181 | ||
| Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT) | Q81681821 | ||
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | computed tomography | Q32566 |
| patient | Q181600 | ||
| bevacizumab | Q413299 | ||
| P304 | page(s) | 2338-2344 | |
| P577 | publication date | 2009-12-01 | |
| P1433 | published in | The Journal of the American Medical Association | Q1470970 |
| P1476 | title | Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases | |
| P478 | volume | 302 |
| Q57088820 | A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection |
| Q39567268 | A reversal in the vascularity of metastatic liver tumors from colorectal cancer after the cessation of chemotherapy plus bevacizumab: contrast-enhanced ultrasonography and histological examination |
| Q37375737 | Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases |
| Q51167584 | Advances in hepato-pancreato biliary surgery. |
| Q38230654 | Advances in understanding of colorectal liver metastasis and implications for the clinic |
| Q53779084 | Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Comple |
| Q38554714 | An overview of experimental and investigational multikinase inhibitors for the treatment of metastatic colorectal cancer. |
| Q38594431 | An overview of imaging techniques for liver metastases management. |
| Q59330131 | Anal canal adenocarcinoma with neuroendocrine features accompanying secondary extramammary Paget disease, successfully treated with modified FOLFOX6: a case report |
| Q38219290 | Anti-EGFR MoAb treatment in colorectal cancer: limitations, controversies, and contradictories |
| Q33770680 | Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions |
| Q42402968 | Antiangiogenesis therapy in the treatment of metastatic colorectal cancer |
| Q37632167 | Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies |
| Q60961748 | Apatinib for treating advanced intrahepatic cholangiocarcinoma after failed chemotherapy: A case report and literature review |
| Q53521945 | Assessment of the residual tumour of colorectal liver metastases after chemotherapy: diffusion-weighted MR magnetic resonance imaging in the peripheral and entire tumour. |
| Q46183954 | Bevacizumab treatment before resection of colorectal liver metastases: safety, recovery of liver function, pathologic assessment |
| Q27026936 | Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis |
| Q37821843 | Biologic modulation of chemotherapy in patients with hepatic colorectal metastases: the role of anti-VEGF and anti-EGFR antibodies |
| Q37114675 | Biomarker in Colorectal Cancer. |
| Q37132680 | Biomarkers in advanced colorectal cancer: challenges in translating clinical research into practice |
| Q37815281 | Biomarkers to predict the clinical efficacy of bevacizumab in cancer |
| Q56541933 | CT attenuation of liver metastases before targeted therapy is a prognostic factor of overall survival in colorectal cancer patients. Results from the randomised, open-label FIRE-3/AIO KRK0306 trial |
| Q36719842 | CT texture analysis in colorectal liver metastases: A better way than size and volume measurements to assess response to chemotherapy? |
| Q52645869 | Capillary density has no value as an early biomarker of bevacizumab efficacy in metastatic colorectal cancers: a prospective clinical trial. |
| Q36145455 | Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies |
| Q49603085 | Changes in CT morphology can be an independent response marker for patients receiving regorafenib for colorectal liver metastases: retrospective pilot study |
| Q35869753 | Clinical Implication of Anti-Angiogenic Effect of Regorafenib in Metastatic Colorectal Cancer |
| Q90318346 | Colorectal cancer: Parametric evaluation of morphological, functional and molecular tomographic imaging |
| Q43831967 | Colorectal liver metastases |
| Q42814001 | Comment on 'Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab'. |
| Q54578237 | Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. |
| Q87420623 | Comparison of various surgical approaches for extensive bilateral colorectal liver metastases |
| Q35172858 | Complete clinical response of liver metastasis after chemotherapy: To resect or not? |
| Q58604734 | Comprehensive Complication Index Validates Improved Outcomes Over Time Despite Increased Complexity in 3707 Consecutive Hepatectomies |
| Q47784299 | Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival |
| Q38676906 | Computed Tomography Image Texture: A Noninvasive Prognostic Marker of Hepatic Recurrence After Hepatectomy for Metastatic Colorectal Cancer |
| Q36545344 | Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy |
| Q37582423 | Computed tomograpy evaluation of morphological changes, clinical response and survival in colorectal cancer liver metastasis treated by regorafenib: A case report |
| Q36295403 | Computerized PET/CT image analysis in the evaluation of tumour response to therapy |
| Q42772471 | Correlation between calcified liver metastases and histopathology of primary colorectal carcinoma in Chinese |
| Q50996706 | Correlation between response to chemotherapy with concomitant bevacizumab for hepatic metastasis of colorectal cancer and degree of enhancement using contrast-enhanced computed tomography. |
| Q83380321 | Curable metastatic colorectal cancer |
| Q38241395 | Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013. |
| Q90094710 | Current state of the art imaging approaches for colorectal liver metastasis |
| Q37832504 | Cytotoxic triplets plus a biologic: state-of-the-art in maximizing the potential of up-front medical treatment of metastatic colorectal cancer. |
| Q55223036 | DNA damage predicts prognosis and treatment response in colorectal liver metastases superior to immunogenic cell death and T cells. |
| Q51070829 | Defining an optimal surgical strategy for synchronous colorectal liver metastases: staged versus simultaneous resection? |
| Q27014926 | Development of a research agenda for the management of metastatic colorectal cancer: proceedings from a multidisciplinary research consensus panel |
| Q38412364 | Diagnostic imaging of pancreatic neuroendocrine neoplasms (pNEN): tumor detection, staging, prognosis, and response to treatment. |
| Q43155567 | Does bevacizumab have a protective effect on hepatotoxicity induced by chemotherapy? |
| Q47108263 | Early morphological change for predicting outcome in metastatic colorectal cancer after regorafenib |
| Q91590197 | Early response evaluation during preoperative chemotherapy for colorectal liver metastases: Combined size and morphology-based criteria predict pathological response and survival after resection |
| Q42002303 | Early tumor cavitation with regorafenib in metastatic colorectal cancer: A case report. |
| Q55125985 | Embryonic Origin of Primary Colon Cancer Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colon Cancer Liver Metastases. |
| Q36832118 | Evaluation of cancer treatment in the abdomen: Trends and advances |
| Q96231885 | Evaluation of liver tumour response by imaging |
| Q50331322 | Evaluation of response after SBRT for liver tumors |
| Q41962463 | Evaluation of therapeutic effect of tumor-targeted therapy |
| Q37821854 | Extending limits of resection for metastatic colorectal cancer: risk benefit ratio. |
| Q90707845 | FDG-PET reflects tumor viability on SUV in colorectal cancer liver metastasis |
| Q28066171 | FIRST BRAZILIAN CONSENSUS ON MULTIMODAL TREATMENT OF COLORECTAL LIVER METASTASES. MODULE 1: PRE-TREATMENT EVALUATION |
| Q33889809 | FLT-PET for early response evaluation of colorectal cancer patients with liver metastases: a prospective study |
| Q61628304 | FOLFIRI with cetuximab or bevacizumab: FIRE-3 |
| Q34745831 | FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer. |
| Q48227698 | Fluorine-18-fluorodeoxyglucose positron emission tomography as an objective substitute for CT morphologic response criteria in patients undergoing chemotherapy for colorectal liver metastases |
| Q44751710 | From multidisciplinary to personalized treatment of colorectal liver metastases: 4 reasons to consider RAS. |
| Q27008428 | Future directions for monitoring treatment response in colorectal cancer |
| Q27852191 | Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab. |
| Q85743813 | Good candidates for a third liver resection of colorectal metastasis |
| Q34373547 | Hepatectomy for recurrent colorectal liver metastases after radiofrequency ablation |
| Q53178962 | Hepatic colorectal cancer metastases showing a distinctive pattern of pathological response after metronomic capecitabine and bevacizumab. |
| Q34743458 | High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome |
| Q36959113 | Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab. |
| Q37513083 | How to assess the efficacy or failure of targeted therapy: Deciding when to stop sorafenib in hepatocellular carcinoma |
| Q36769581 | Image-based response assessment of liver metastases following stereotactic body radiotherapy with respiratory tracking |
| Q28067562 | Imaging in Colorectal Cancer: Progress and Challenges for the Clinicians |
| Q26863654 | Imaging-based tumor treatment response evaluation: review of conventional, new, and emerging concepts |
| Q90117044 | Impact of Genetics on Neoadjuvant Therapy with Complete Pathological Response in Metastatic Colorectal Cancer: Case Report and Review of the Literature |
| Q50086554 | Impact of RAS Mutations in Metastatic Colorectal Cancer After Potentially Curative Resection: Does Site of Metastases Matter? |
| Q50001196 | Individualized Treatment Sequencing Selection Contributes to Optimized Survival in Patients with Rectal Cancer and Synchronous Liver Metastases |
| Q45141490 | Intraoperative detection of disappearing colorectal liver metastases as a predictor of residual disease |
| Q38110741 | Intravoxel incoherent motion (IVIM) MR imaging of colorectal liver metastases: are we only looking at tumor necrosis? |
| Q38796209 | Is regorafenib providing clinically meaningful benefits to pretreated patients with metastatic colorectal cancer? |
| Q35082383 | Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified? |
| Q56524446 | Late gadolinium enhancement of colorectal liver metastases post-chemotherapy is associated with tumour fibrosis and overall survival post-hepatectomy |
| Q57280710 | Liquid biopsies to evaluate early therapeutic response in colorectal cancer: Figure 1 |
| Q37951604 | Liver metastases from colorectal cancer: how to best complement medical treatment with surgical approaches. |
| Q37904901 | Liver resection for advanced or aggressive colorectal cancer metastases in the era of effective chemotherapy: a review |
| Q47869784 | Liver transarterial embolizations in metastatic neuroendocrine tumors |
| Q47129929 | Long-term postoperative survival prediction in patients with colorectal liver metastasis |
| Q51728554 | Management of colorectal liver metastases: past, present, and future. |
| Q36844084 | Margin status remains an important determinant of survival after surgical resection of colorectal liver metastases in the era of modern chemotherapy |
| Q35709696 | Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases |
| Q37375230 | Modified two-dimensional response as surrogate marker of overall survival in patients with metastatic colorectal cancer. |
| Q37589551 | Molecular Targeted Therapy in Modern Oncology: Imaging Assessment of Treatment Response and Toxicities |
| Q38938329 | Molecular markers of prognosis and therapeutic targets in metastatic colorectal cancer. |
| Q55347051 | Monitoring circulating tumor DNA revealed dynamic changes in KRAS status in patients with metastatic colorectal cancer. |
| Q41142528 | Morphological response contributes to patient selection for rescue liver resection in chemotherapy patients with initially un-resectable colorectal liver metastasis |
| Q37582863 | Multicenter validation study of pathologic response and tumor thickness at the tumor-normal liver interface as independent predictors of disease-free survival after preoperative chemotherapy and surgery for colorectal liver metastases |
| Q57132503 | Multimodality Treatment of a Colorectal Cancer Stage IV Patient with FOLFOX-4, Bevacizumab, Rigvir Oncolytic Virus, and Surgery |
| Q92915888 | Mutation Status of RAS, TP53, and SMAD4 is Superior to Mutation Status of RAS Alone for Predicting Prognosis after Resection of Colorectal Liver Metastases |
| Q37969833 | Neoadjuvant and adjuvant therapy in relation to surgery for colorectal liver metastases |
| Q36343047 | Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agents |
| Q37821842 | Neoadjuvant therapy of colorectal liver metastases: lessons learned from clinical trials. |
| Q49901550 | Neuroendocrine Carcinoma of the Stomach: A Response to Combination Chemotherapy Consisting of Ramucirumab Plus Paclitaxel |
| Q64985818 | New PET/CT Features for the Evaluation of Tumor Response. |
| Q37876335 | New acquisition techniques: fields of application |
| Q53133372 | New perspectives for TAS-102: TASK successful? |
| Q89228423 | Non Size Based Morphology Criteria for Assessment of Response in Patients with Liver Metastases of Gastrointestinal Origin Receiving Systemic Treatment |
| Q36860539 | Non-size-based response criteria to preoperative chemotherapy in patients with colorectal liver metastases: the morphologic response criteria |
| Q38264850 | Nonsurgical giant cell tumour of the tendon sheath or of the diffuse type: are MRI or 18F-FDG PET/CT able to provide an accurate prediction of long-term outcome? |
| Q90056572 | Objective response rate assessment in oncology: Current situation and future expectations |
| Q38064752 | Oncological management of unresectable liver metastases |
| Q36457189 | Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases |
| Q37782046 | Optimizing resection for “responding” hepatic metastases after neoadjuvant chemotherapy |
| Q50911525 | PLK-1 Expression is Associated with Histopathological Response to Neoadjuvant Therapy of Hepatic Metastasis of Colorectal Carcinoma. |
| Q88018086 | Pathologic assessment of response to chemotherapy in colorectal cancer liver metastases after hepatic resection: which method to use? |
| Q41234320 | Pathological complete response after neoadjuvant chemotherapy for rectal cancer with synchronous multiple liver metastases: a report of an unusual case |
| Q58199973 | Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases |
| Q91383759 | Perfusion Quantification of Liver Metastases of Colorectal Cancer Treated with Anti-angiogenic-Based Therapy: Assessment of Intra- and Inter-observer Reproducibility of Parameters in Three Regions of Interest Outlining Lesions |
| Q61813148 | Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors |
| Q38791333 | Planned Treatment of Advanced Metastatic Disease with Completion Ablation After Hepatic Resection |
| Q27009240 | Positron Emission Tomography for the Response Evaluation following Treatment with Chemotherapy in Patients Affected by Colorectal Liver Metastases: A Selected Review |
| Q37444081 | Positron emission tomography/computerized tomography for tumor response assessment-a review of clinical practices and radiomics studies |
| Q85001765 | Postchemotherapy histological analysis of major intrahepatic vessels for reversal of attachment or invasion by colorectal liver metastases |
| Q36869744 | Potential Prognostic Impact of Baseline CEA Level and Surgery of Primary Tumor Among Patients with Synchronous Stage IV Colorectal Cancer: A Large Population Based Study |
| Q35835193 | Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients |
| Q51193100 | Preoperative bevacizumab and surgery for colorectal liver metastases: a propensity score analysis. |
| Q90448739 | Preoperative chemotherapy in colorectal cancer patients with synchronous liver metastasis |
| Q26774687 | Preoperative selection of patients with colorectal cancer liver metastasis for hepatic resection |
| Q85411312 | Preoperative treatment with bevacizumab in combination with chemotherapy in patients with unresectable metastatic colorectal carcinoma |
| Q88298789 | Prognostic Impact of Change in the Fibrinogen and Albumin Score During Preoperative Treatment in Esophageal Cancer Patients |
| Q40674654 | Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations |
| Q38068492 | Prognostic factors after resection of colorectal liver metastases: from morphology to biology. |
| Q38925427 | Prognostic impact of margin status in liver resections for colorectal metastases after bevacizumab. |
| Q36084851 | Prognostic value of different CT measurements in early therapy response evaluation in patients with metastatic colorectal cancer |
| Q52647388 | Progression of Colorectal Cancer Liver Metastasis After Chemotherapy: A New Test of Time? |
| Q41339254 | Pseudoprogression in microsatellite instability-high colorectal cancer during treatment with combination T cell mediated immunotherapy: a case report and literature review |
| Q48300792 | Pseudoprogression on bevacizumab treatment: tumor-dynamics in the modern era of systemic treatment for metastatic colorectal cancer. |
| Q89160917 | Quantitative imaging features of pretreatment CT predict volumetric response to chemotherapy in patients with colorectal liver metastases |
| Q37375848 | RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases |
| Q35054390 | RAS mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases. |
| Q53527483 | Radiological Morphology of Colorectal Liver Metastases after Preoperative Chemotherapy Predicts Tumor Viability and Postoperative Outcomes. |
| Q54002435 | Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study). |
| Q89522016 | Radiomics Response Signature for Identification of Metastatic Colorectal Cancer Sensitive to Therapies Targeting EGFR Pathway |
| Q35767565 | Recent advances in the curative treatment of colorectal liver metastases |
| Q38135754 | Recommendations of a group of experts for the pathological assessment of tumour regression of liver metastases of colorectal cancer and damage of non-tumour liver tissue after neoadjuvant therapy. |
| Q95539673 | Regorafenib for metastatic colorectal cancer |
| Q31131324 | Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry. |
| Q38602133 | Remnant Liver Ischemia as a Prognostic Factor for Cancer-Specific Survival After Resection of Colorectal Liver Metastases |
| Q46972090 | Response to preoperative chemotherapy predicts survival in patients undergoing hepatectomy for liver metastases from gastric and esophageal cancer |
| Q90627128 | SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018) |
| Q47744121 | SEOM/SERAM consensus statement on radiological diagnosis, response assessment and follow-up in colorectal cancer |
| Q45296595 | SSAT State-of-the-Art Conference: New Frontiers in Liver Surgery. |
| Q38166820 | Selected gastrointestinal cancer presentations from the American Society of Clinical Oncology annual meeting 2013 in review: it is not about the destination, it is about the journey |
| Q33906344 | Selection criteria for radiofrequency ablation for colorectal liver metastases in the era of effective systemic therapy: a clinical score based proposal |
| Q30415026 | Selection for hepatic resection of colorectal liver metastases: expert consensus statement |
| Q92526836 | Serial Monitoring of Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer to Predict the Therapeutic Response |
| Q38831804 | Stereotactic body radiation therapy of liver tumors: post-treatment appearances and evaluation of treatment response: a pictorial review. |
| Q27694490 | Surgery for colorectal liver metastases: The evolution of determining prognosis |
| Q28075777 | Surgical Management of Colorectal Liver Metastases: Prognostic Indicators and the Impact of RAS Mutation Status |
| Q90094706 | Surgical approach to synchronous colorectal liver metastases: staged, combined, or reverse strategy |
| Q38064750 | Surgical strategies to synchronous colorectal liver metastases. |
| Q38888162 | Surrogate Imaging Biomarkers of Response of Colorectal Liver Metastases After Salvage Radioembolization Using 90Y-Loaded Resin Microspheres. |
| Q37037106 | Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement |
| Q38800002 | The Attenuation Distribution Across the Long Axis (ADLA): Preliminary Findings for Assessing Response to Cancer Treatment |
| Q53645661 | The Role of Neoadjuvant Therapy in Characterizing Indeterminate Lung Lesions in Patients with Resectable Colorectal Liver Metastases. |
| Q91341298 | The beginning of the end for conventional RECIST - novel therapies require novel imaging approaches |
| Q36349575 | The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus |
| Q38209147 | The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status |
| Q35076305 | The role of peri-operative treatment in resectable liver metastases of colorectal cancer |
| Q55424081 | Thymidylate synthase expression in primary colorectal cancer as a predictive marker for the response to 5-fluorouracil- and oxaliplatin-based preoperative chemotherapy for liver metastases. |
| Q26797292 | Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials |
| Q37855303 | Treatment recommendations for metastatic colorectal cancer |
| Q35622772 | Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG). |
| Q35670736 | Tumor T1 Relaxation Time for Assessing Response to Bevacizumab Anti-Angiogenic Therapy in a Mouse Ovarian Cancer Model |
| Q39357256 | Tumor and non-tumor liver angiogenesis is traced and evaluated by hepatic arterial ultrasound in murine models |
| Q45032127 | Tumor histopathology predicts outcomes after resection of colorectal cancer liver metastases treated with and without pre-operative chemotherapy |
| Q35285305 | Update on the role of imaging in management of metastatic colorectal cancer |
| Q36286704 | Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer |
| Q37407384 | Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases |
| Q36999699 | What is the optimal neo-adjuvant treatment for liver metastasis? |
| Q86998280 | [Computed tomographic morphological evaluation of neoadjuvant chemotherapy. Effectiveness of the therapy for colorectal liver metastases] |
Search more.